The First Take: Ocrevus, the first treatment for progressive MS - KOLs speak out

FirstWord's Duncan Emerton - Senior Director of Syndicated Insights and Analysis - and François Pagnini - Lead Analyst - discuss some of the key findings from a new KOL Insight: Multiple Sclerosis report.

New Report - Multiple Sclerosis: KOL Insight

How will Ocrevus reshape the MS treatment landscape?

A multitude of recent approvals and launches are changing the way MS is treated, but what does the future hold? Key opinion leaders (KOLs) are excited about Ocrevus’ approval in relapsing and progressive forms of the disease and Mavenclad’s European approval gives patients another treatment choice, but which therapy will stand out in an evolving and competitive landscape? Other disease modifying therapies are in late-stage development but which segment of the market can they expect to capture? Learn how KOLs see the market evolving, and how they expect developers to differentiate their marketed and pipeline therapies in KOL Insight: Multiple Sclerosis. Twelve of the world’s most prominent KOLs provide their candid insights on ten marketed products and seven Phase III pipeline programmes.

To read more Analyst Notes articles, click here.